Analgesic Efficacy and Safety of V116517 in Subjects With Moderate to Severe Chronic Pain Due to Osteoarthritis (OA) of the Knee
Status: | Completed |
---|---|
Conditions: | Arthritis, Chronic Pain, Osteoarthritis (OA) |
Therapuetic Areas: | Musculoskeletal, Rheumatology |
Healthy: | No |
Age Range: | 40 - 80 |
Updated: | 5/27/2013 |
Start Date: | September 2012 |
End Date: | January 2014 |
Contact: | Study Coordinator |
Phone: | 1-877-333-0076 |
A Phase 2, Randomized, Double-blind, Placebo- and Active-controlled, Parallel-group, Multicenter Study Evaluating the Analgesic Efficacy and Safety of V116517 in Subjects With Moderate to Severe Chronic Pain Due to Osteoarthritis of the Knee
The primary objective of this study is to evaluate the analgesic efficacy of 2 dose levels
of V116517 versus placebo.
Key Inclusion Criteria:
1. Subjects with moderate pain due to OA of the knee as their primary pain condition.
2. Subjects with diagnostic criteria for primary pain condition (American college of
Rheumatology [ACR] clinical and radiographic criteria):
- At least 1 of the following in addition to knee pain: age >50, stiffness <30
min, crepitus on active motion, and
- Kellgren-Lawrence (K-L) grade ≥ 2 radiographic evidence within the past 2 years.
Key Exclusion Criteria:
1. Subjects with chronic pain conditions other than OA of the knee as their predominant
pain condition, including gout, pseudo gout, psoriatic arthritis, active Lyme
disease, rheumatoid arthritis or any other inflammatory arthritis, fibromyalgia,
neuropathic pain conditions, bursitis, or acute injury or signs of active infection
in the target pain area.
2. Subjects who cannot or will not agree to stop all concomitant analgesic medications,
apart from specified protocol supplemental analgesic medications.
3. Subjects with history of seizures within the past 5 years.
4. Subjects who use opioids more than 4 days per week.
5. Pain-condition-specific exclusions:
- Subjects who received local pain-control procedures, including intra-
articular steroid injection in the study knee or intramuscular steroid injection
at any site within 6 weeks of entering the study or hyaluronate injection in the
study knee within 12 weeks of entering the study.
6. Subjects who have had arthroscopy on either knee or hip within 6 months of entering
the study, or open surgery on either knee or hip within 12 months of entering the
study.
7. Active-comparator-related exclusions:
- Subjects who are allergic to or cannot tolerate naproxen or acetaminophen,
including history of NSAID-induced asthma, or nasal polyps;
- Subjects with history of bleeding disorders or history of documented
gastrointestinal ulcer disease.
Other protocol specific inclusion/exclusion criteria may apply.
We found this trial at
18
sites
Click here to add this to my saved trials
Site Overview Avail Clinical Research is a renowned and experienced clinical research site conducting Phase...
Click here to add this to my saved trials
Click here to add this to my saved trials
Compass Research LLC Compass Research is a clinical research company dedicated to testing new medications...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Wake Research Associates, LLC Wake Research is an Organization of Unified Investigational Sites working closely...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials